| ¿µ¹® | Parkinson disease | ÇÑ±Û | ÆÄŲ½¼º´ |
|---|---|---|---|
| ¼³¸í | ³ªÀÌµç »ç¶÷¿¡°Ô ¹ß»ýÇÏ´Â ½Å°æ°èÀÇ ÅðÇິÀÌ´Ù. ÁÖ·Î ¿îµ¿À» ´ã´çÇÏ´Â Áß°£³úºÎÀ§°¡ ħ¹üµÈ´Ù. ¿øÀÎÀº ¹ÙÀÌ·¯½º, ¾à¹°, ȤÀº µ¿¸Æ°æÈÁõ µîÀ¸·Î ¾Ë·ÁÁø °æ¿ìµµ ÀÖÀ¸³ª, ¿øÀÎÀ» ¾Ë ¼ö ¾ø´Â °æ¿ì°¡ ¸¹´Ù. Áõ»óÀº °¡¸é¾ó±¼, ¾²·¯Áú °Í °°Àº °ÉÀ½°ÉÀÌ, ¼Õ¶³¸², ±ÙÀ°ÀÇ °Á÷, ¾ÕÀ¸·Î ±â¿ï¾îÁø ÀÚ¼¼ µîÀÓ. Ä¡·á´Â Ưº°ÇÑ °ÍÀÌ ¾øÀ¸¸ç, ´ë°³ º¸Á¸Àû Ä¡·á(¿ÏÄ¡¸¦ ¸ñÀûÀ¸·Î ÇÏÁö ¾Ê°í ´ÜÁö ȯÀÚÀÇ »ýȰÀ» º¸Á¶ÇØÁÖ´Â Á¤µµÀÇ Ä¡·á)¸¦ ½ÃÇàÇÑ´Ù. ÃÖ±Ù, Á×Àº žÆÀÇ ³ú¸¦ À̽ÄÇÏ´Â ³ú À̽ļú¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù´Â º¸°í°¡ ÀÖ´Ù. |
||
| ¿µ¹® | infectious disease | ÇÑ±Û | °¨¿°º´ |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º·ÎºÎÅÍ ±â»ýÃæ Å©±â±îÁöÀÇ »ý¹°À» ¿øÀÎÀ¸·Î ÇÏ´Â º´. ¿øÀÎÀº Á¢ÃËÀü¿°¼ºÀ̸ç, º´¿ø¿¡¼ °¨¿°µÇ´Â °æ¿ìµµ ÀÖ´Ù. °¨¿°À» ¿øÀαտ¡ µû¶ó ºÐ·ùÇÏ¸é ¹ÙÀÌ·¯½º, ¼¼±Õ, Ŭ¶ó¹Ìµð¾Æ, ¸®ÄÏÂ÷, ¹ÌÄÚ¹ÚÅ׸®¿ò, °õÆÎÀÌ, ¿øÃæ, À±Ãæ, ¿ÜºÎ±â»ýÃæ °¨¿°À¸·Î ³ª´ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | hypertensive heart disease | ÇÑ±Û | °íÇ÷¾Ð½ÉÀ庴 |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾Ð¿¡ ÀÇÇØ¼ »ý±â´Â ½ÉÀ庴. °íÇ÷¾Ð½ÉÀ庴À̶ó´Â Áø´ÜÀ» ºÙÀ̱â À§Çؼ´Â ÃÖ¼ÒÇÑ ´ÙÀ½°ú °°Àº Á¶°ÇÀÌ ºÎÇյǾî¾ß Çϴµ¥, ù° ½ÉÀåÇ÷°ü°è¿¡ ½ÉÀ庴À» À¯¹ßÇÒ ¼ö ÀÖÀ» ¸¸ÇÑ ´Ù¸¥ º´º¯ÀÌ ¾øÀÌ ÁÂ½É½Ç ºñ´ë°¡ ÀÖ¾î¾ß Çϸç, µÑ° °íÇ÷¾ÐÀ» ¾Î¾Ò´Ù´Â º´·ÂÀÌ ÀÖ¾î¾ß ÇÑ´Ù. ÁÖ·Î °íÇ÷¾Ð¿¡ ÀÇÇÑ ½ÉÀ庴Àº Ãʱ⿡´Â Á½ɽÇÀÌ ºñÈĶó´Â °ÍÀ¸·Î Ư¡µÇ¾îÁø´Ù. Áï Ç÷¾ÐÀÌ ³ôÀ¸¹Ç·Î Ç÷¾×À» ¼øÈ¯½Ã۱â À§Çؼ´Â ±×¸¸Å ½ÉÀåÀÇ Ç÷¾×À» º¸³»´Â ÈûÀÌ ÁÁ¾Æ¾ß ÇÑ´Ù. ±× ÈûÀ» ¾ò±âÀ§Çؼ´Â ½É±ÙÀÇ ºñÈİ¡ ÇÊ¿ä·Î ÇÏ¿© ÁÂ½É½Ç ±ÙÀ°ÀÇ ºñÈİ¡ »ý±ä´Ù. ±×¸®°í °íÇ÷¾ÐÀÌ Áö¼ÓÀÌ µÉ °æ¿ì¿¡´Â °á±¹ ½ÉÀåÀÌ Á¦ ±¸½ÇÀ» ÇÏÁö ¸øÇÏ°í ÆßÇÁ·Î¼ÀÇ ±â´ÉÀ» ÀÒ¾î¹ö¸®°Ô µÇ¾î ½ÉÀå±â´É»ó½Ç¿¡ ºüÁö°Ô µÈ´Ù. |
||
| ¿µ¹® | pelvic inflammatory disease | ÇÑ±Û | °ñ¹Ý¿°Áúȯ |
|---|---|---|---|
| ¼³¸í | °ñ¹ÝÁÖÀ§ÀÇ Àå±â¿¡ ¹ß»ýÇÏ´Â ¿°ÁõÀ» ¸»ÇÔ. ÁÖ·Î ¿©¼º¿¡¼ ¹ß»ýÇÏ¸ç ¿øÀÎÀº ÀÓ±Õ(gonococcus)°ú ºñÀÓ±Õ¿¡ ÀÇÇÑ °¨¿°(non-gonorrheal infection)¿¡ ÀÇÇÑ´Ù. Áõ»óÀº Ãʱ⿡´Â ÁúºÐºñ¹°, ÇϺ¹ºÎµ¿Åë, ¿©¼ºÀÇ »ý½Ä±âºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¾ÐÅë, ¿ù°æÅë, ¿ù°æ·®ÀÇ Áõ°¡ µîÀÌ´Ù. ÀÏÂï Ä¡·áÇØ¾ß Çϸç, °è¼ÓÀûÀ¸·Î º´ÀÌ Áö¼Ó½Ã ¿©¼ºÀÇ ºÒÀÓÀÇ ¿øÀÎÀÌ µÈ´Ù. ÈÄÁø±¹¿¡¼´Â °¡Àå ¸¹Àº ¿©¼ººÒÀÓÀÇ ¿øÀÎÀ̱⵵ ÇÔ. Ä¡·á´Â Ç×»ýÁ¦ÀÇ Åõ¿©ÀÌ´Ù. |
||
| ¿µ¹® | Graves' disease | ÇÑ±Û | ±×·¹À̺꽺º´ |
|---|---|---|---|
| ¼³¸í | °©»ó»ùÀÇ ºñ´ë¿Í °©»ó»ùÈ£¸£¸óÀÇ °ú´ÙºÐºñ°¡ Ư¡ÀÎ º´ÀÌ´Ù. ÀÌ º´Àº ÁÖ·Î 25~50¼¼¿¡ È£¹ßÇϰí ÁÖ·Î ¿©ÀÚ¿¡°Ô¼ ¸¹ÀÌ »ý±ä´Ù. °©»ó»ù È£¸£¸óÀº ÀúÀåµÇ¾î ÀÖ´Â ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ¿© ½ÅüÀÇ ´ë»çÀ²À» ³ôÀ̴ ȣ¸£¸óÀ̹ǷΠÀÔ¸ÀÀÌ ÁÁÀº µ¥µµ ºÒ±¸ÇÏ°í °è¼ÓÀûÀΠüÁßÀÇ °¨¼Ò, ±×¸®°í ÃàÀûµÈ ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ¿© ¿»ý¸¹ÀÌ ÇÏ¿©¼ ´õÀ§¸¦ Âü±â Èûµé¾îÇÏ°í ¸¸¼º ¼è¾à°¨À̳ª ±Ù·ÂÀÇ ¾àȸ¦ º¸ÀÏ ¼ö°¡ ÀÖ´Ù. ±×¸®°í ´«¿¡ Ư¡ÀûÀÎ Áõ»óÀÌ ³ªÅ¸³ª´Âµ¥ ´«²¨Ç®ÀÌ ºñÁ¤»óÀûÀ¸·Î À§·Î ¿Ã¶ó°¡ ÀÖ°í, ´«ÀÌ ¾Æ·¡ÀÇ ¹°°ÇÀ» ÁÖ½ÃÇÒ °æ¿ì¿¡ ´«²¨Ç®ÀÌ Á¤»óÀûÀ¸·Î´Â óÁ®¾ß ÇÏÁö¸¸ °©»ó»ù È£¸£¸óÀÌ °úµµÇÏ°Ô ³ª¿Ã °æ¿ì¿¡´Â ´«²¨Ç®ÀÌ Ã³ÁöÁö ¾Ê´Â´Ù. ¶Ç ´«¾ËÀÌ ¾ÕÂÊÀ¸·Î µ¹ÃâÇÏ´Â ¾È±¸µ¹ÃâÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¶Ç ÇǺΰ¡ ¾ÆÁÖ ºÎµå·´°í ¹°±â°¡ ¸¹¾Æ¼ ÃàÃàÇÏ´Ù. ±×¸®°í Ư¡ÀûÀ¸·Î ÇÏÁöÀÇ ¾ÕÂÊ¿¡ ÇǺΰ¡ µÎ²¨¿öÁ® ±¹¼ÒÀû À¶±â¸¦ ÀÌ·ç´Â °ÍÀÌ Àִµ¥ À̰ÍÀº ÀÌ º´ÀÇ Æ¯Â¡ÀûÀÎ º´ÅÍÀÌ´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| PD | Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p... |
| PMD | Progressive Muscular Dystrophy; ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ Types of PMD(Progressive Muscular Dystroph... |
| TAPVR | Total Anomalous Pulmonary Venous Return = TAPVC 4 Types of TAPVR &... |
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| IPD | Idiopathic Parkinson's disease |
|---|---|
| PD | Parkinson Disease |
| PDQ-39 | Parkinson's Disease Questionnaire |
| UPDRS | Unified Parkinson Disease Rating Scale |
| PD | Parkinson |
| parkinson disease | Progressive, degenerative disease of unknown aetiology characterised by rhythmic tremor of the limbs, stooped posture, slowness of voluntary movements, and masklike facial expression. Pathologically there is nerve cell loss in the melanin-containing cells in the brainstem and a corresponding reduction in dopamine levels in the corpus striatum. Lewy bodies are present in the substantia nigra and locus coeruleus. (12 Dec 1998) |
|---|---|
| parkinson disease, postencephalitic | A form of parkinson disease due to degeneration of the corpus striatum or substantia nigra, frequently occurring as a sequel of lethargic encephalitis. The early age of onset, the rapid progression of symptoms and signs of stabilization, and the presence of a variety of other neurological disorders (sociopathic behaviour, tics, spasms, oculogyric crises and other restricted motor disorders, breathing arrhythmias, hyperphagia, and bizarre movements, postures, and gaits) distinguish this disease from the one described by parkinson. (12 Dec 1998) |
| parkinson disease, symptomatic | Symptoms of parkinson disease induced by drugs, or following cerebral arteriosclerosis, brain tumour, or other central nervous system disorders except encephalitis, which is parkinson disease, postencephalitic. (12 Dec 1998) |
| Parkinson's disease | <neurology> A progressive, neurological disease first described in 1817 by James Parkinson. The pathology is not completely understood, but there appears to be consistent changes in the melanin-containing nerve cells in the brainstem (substantia nigra, locus coeruleus), where there are varying degrees of nerve cell loss with reactive gliosis along with eosinophilic intracytoplasmic inclusions (Lewy bodies). Biochemical studies have shown below normal levels of dopamine in the caudate nucleus and putamen. Symptoms include shuffling gait, stooped posture, resting tremor, speech impediments, movement difficulties and an eventual slowing of mental processes and dementia. (27 Sep 1997) |
| disease, parkinson's | An abnormal condition of the nervous system caused by degeneration of an area of the brain called the basal ganglia. The disease results in rigidity of the muscles, slow body movement and tremor. Parkinson's disease is also called paralysis agitans and shaking palsy. (12 Dec 1998) |
| type I familial hyperlipoproteinaemia | Hyperlipoproteinaemia characterised by the presence of large amounts of chylomicrons and triglycerides in the plasma when the patient has a normal diet, and their disappearance on a fat-free diet; low alpha-and beta-lipoproteins on a normal diet, with increase on fat-free diet; decreased plasma postheparin lipolytic activity; and low tissue lipoprotein lipase activity. It is accompanied by bouts of abdominal pain, hepatosplenomegaly, pancreatitis, and eruptive xanthomas; autosomal recessive inheritance. See: familial lipoprotein lipase inhibitor. Synonym: Burger-Grutz syndrome, familial fat-induced hyperlipaemia, familial hyperchylomicronaemia, familial hypertriglyceridemia, idiopathic hyperlipaemia. (05 Mar 2000) |
| type II familial hyperlipoproteinaemia | Hyperlipoproteinaemia characterised by increased plasma levels of beta-lipoproteins, cholesterol, and phospholipids, but normal triglycerides; heterozygotes have mild lipid changes and are susceptible to atherosclerosis in middle age, but homozygotes have severe changes often with generalised xanthomatosis and xanthelasma, and frank clinical atherosclerosis as young adults. The primary defect is a deficiency of apoprotein of VLDL, and the disorder is divided into two classes: 1) type IIA, which has elevated LDL due to a deficiency of the receptor or a modified apolipoprotein B-100; 2) type IIB, which has elevated LDL and triglycerides; autosomal dominant inheritance. Synonym: familial hyperbetalipoproteinaemia, familial hypercholesteraemic xanthomatosis, familial hypercholesterolaemia. (05 Mar 2000) |
| type III familial hyperlipoproteinaemia | Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties. Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia. (05 Mar 2000) |
| type IV familial hyperlipoproteinaemia | Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance. Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia. (05 Mar 2000) |
| type V familial hyperlipoproteinaemia | Hyperlipoproteinaemia characterised by increased plasma levels of chylomicrons, VLDL, pre-beta-lipoproteins, and triglycerides, and slight rise of cholesterol on a normal diet, with beta-lipoproteins normal; may be accompanied by bouts of abdominal pain, hepatosplenomegaly, susceptibility to atherosclerosis, and abnormal glucose tolerance; probably autosomal recessive inheritance. Synonym: combined fat-and carbohydrate-induced hyperlipaemia, familial hyperchylomicronaemia with hyperprebetalipoproteinaemia, mixed hyperlipaemia. (05 Mar 2000) |
| Parkinson, James | <person> This English physician is chiefly remembered for his 66-page "Essay on the Shaking Palsy" (first edition is valued at |
| Parkinson's facies | The expressionless or masklike facies characteristic of parkinsonism. Synonym: masklike face. (05 Mar 2000) |
| Parkinson, Sir John | <person> British cardiologist, *1885. See: Wolff-Parkinson-White syndrome. (05 Mar 2000) |
| wolff-parkinson-white syndrome | <syndrome> A form of pre-excitation characterised by a short pr interval and a long qrs interval with a delta wave. (12 Dec 1998) |
| Wolf Parkinson White syndrome | <cardiology, syndrome> Abnormal cardiac conduction that occurs by way of an accessory pathway between the atria and the ventricles. Baseline ECG will typically show a short P-R interval and a slurred upstroke of the QRS (delta wave). Tachyarrhythmias are common. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|